5-(4-methyl-piperazin-1-yl)-quinolin-8-ylamine | 955413-27-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-(4-methyl-piperazin-1-yl)-quinolin-8-ylamine
• 英文别名: 5-(4-methylpiperazin-1-yl)quinolin-8-amine
• CAS: 955413-27-1
• 化学式: C₁₄H₁₈N₄
• mdl: MFCD11980629
• 分子量: 242.324
• InChiKey: ODGVNVGQFVATNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  45.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(8-nitroquinolin-5-yl)morpholine 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 以96%的产率得到5-(4-methyl-piperazin-1-yl)-quinolin-8-ylamine
  参考文献：
  名称：

  Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation

  摘要：

  本文披露了由式(I)或式(II)表示的抑制血管生成的药物： 式(I)和式(II)中的变量在本文中有定义。

  公开号：

  US20070254894A1

文献信息

• Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
  申请人：Sumitomo Pharma Oncology, Inc.

  公开号：US11529350B2

  公开（公告）日：2022-12-20

  Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., X 1 , X 2 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non-receptor 1 (TNK1)-mediated diseases, disorders and conditions.

  本文提供了一种式 I.化合物或其药学上可接受的盐： 或其药学上可接受的盐，其中变量值（如 X 1 , X 2 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 m，n）如本文所述。式 I 的化合物、其药学上可接受的盐、前述任一种的药物组合物以及前述任一种的组合物可用于治疗酪氨酸激酶非受体 1 (TNK1) 介导的疾病、失调和病症。
• WO2021003417A5
  申请人：——

  公开号：WO2021003417A5

  公开（公告）日：2023-08-07
• Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof
  申请人：Sumitomo Dainippon Pharma Oncology, Inc.

  公开号：US20210000825A1

  公开（公告）日：2021-01-07

  Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., X 1 , X 2 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non-receptor 1 (TNK1)-mediated diseases, disorders and conditions.
• [EN] TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TYROSINE KINASE NON RÉCEPTEUR 1 (TNK1) ET LEURS UTILISATIONS
  申请人：SUMITOMO DAINIPPON PHARMA ONCOLOGY INC

  公开号：WO2021003417A1

  公开（公告）日：2021-01-07

  Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non- receptor 1 (TNK1)-mediated diseases, disorders and conditions.